Renovaro Inc
RENB1.420USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
251.90MMarket Cap
LossP/E TTM
More Details of Renovaro Inc Company
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Renovaro Inc Info
Ticker SymbolRENB
Company nameLunai Bioworks Inc
IPO dateNov 18, 2014
CEOWeinstein (David)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 18
Address2080 Century Park East, Suite 906
CityLOS ANGELES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90067
Phone14539179840
Website
Ticker SymbolRENB
IPO dateNov 18, 2014
CEOWeinstein (David)
Company Executives of Renovaro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
BMO Nesbitt Burns Inc.
5.79%
Gumrukcu (Serhat)
5.35%
Other
57.91%
Shareholders
Shareholders
Proportion
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
BMO Nesbitt Burns Inc.
5.79%
Gumrukcu (Serhat)
5.35%
Other
57.91%
Shareholder Types
Shareholders
Proportion
Corporation
31.30%
Investment Advisor
8.84%
Individual Investor
8.20%
Hedge Fund
1.12%
Investment Advisor/Hedge Fund
0.79%
Research Firm
0.03%
Other
49.72%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
144
2.83M
12.20%
+559.32K
2025Q2
156
65.41M
35.65%
+4.54M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
2023Q2
147
41.48M
71.99%
+3.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RS Group ApS
1.68M
7.26%
+322.24K
+23.69%
Jul 15, 2025
Lakysa Ventures, Inc
2.15M
9.27%
+2.15M
--
Jul 15, 2025
PasecoApS
2.70M
11.65%
+1.44M
+113.93%
Jul 15, 2025
BMO Nesbitt Burns Inc.
1.36M
5.86%
+1.36M
--
Jul 15, 2025
Gumrukcu (Serhat)
1.25M
5.4%
--
--
Jul 15, 2025
The Vanguard Group, Inc.
492.46K
2.12%
-73.57K
-13.00%
Jun 30, 2025
William (Anderson Wittekind)
476.63K
2.06%
--
--
Jul 15, 2025
Millennium Management LLC
214.96K
0.93%
+213.51K
+14684.25%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
256.55K
1.11%
-424.73K
-62.34%
Jun 30, 2025
Geode Capital Management, L.L.C.
101.59K
0.44%
-135.17K
-57.09%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 24, 2025
Merger
10→1
Date
Type
Ratio
Sep 24, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Renovaro Inc?
The top five shareholders of Renovaro Inc are:
RS Group ApS holds 1.68M shares, accounting for 7.26% of the total shares.
Lakysa Ventures, Inc holds 2.15M shares, accounting for 9.27% of the total shares.
PasecoApS holds 2.70M shares, accounting for 11.65% of the total shares.
BMO Nesbitt Burns Inc. holds 1.36M shares, accounting for 5.86% of the total shares.
Gumrukcu (Serhat) holds 1.25M shares, accounting for 5.40% of the total shares.
RS Group ApS holds 1.68M shares, accounting for 7.26% of the total shares.
Lakysa Ventures, Inc holds 2.15M shares, accounting for 9.27% of the total shares.
PasecoApS holds 2.70M shares, accounting for 11.65% of the total shares.
BMO Nesbitt Burns Inc. holds 1.36M shares, accounting for 5.86% of the total shares.
Gumrukcu (Serhat) holds 1.25M shares, accounting for 5.40% of the total shares.
What are the top three shareholder types of Renovaro Inc?
The top three shareholder types of Renovaro Inc are:
RS Group ApS
Lakysa Ventures, Inc
PasecoApS
RS Group ApS
Lakysa Ventures, Inc
PasecoApS
How many institutions hold shares of Renovaro Inc (RENB)?
As of 2025Q3, 144 institutions hold shares of Renovaro Inc, with a combined market value of approximately 2.83M, accounting for 12.20% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -23.45%.
What is the biggest source of revenue for Renovaro Inc?
In --, the -- business generated the highest revenue for Renovaro Inc, amounting to -- and accounting for --% of total revenue.
